January 10, 2018
SAN LUIS OBISPO, Calif.–(BUSINESS WIRE)–FzioMed, Inc. a leading biomaterials company, is pleased to announce that Oxiplex sales have now passed the 500,000 unit mark.
Oxiplex is approved outside the United States in more than 70 countries and distributed under various brand names; including, Oxiplex, Oxiplex/SP, MediShield, and Interpose.
Oxiplex is an absorbable gel applied to neural tissues following spine surgery. Oxiplex creates a temporary physical barrier between adjacent tissues and has been shown in multiple peer reviewed studies to reduce leg pain, back pain, and neurologic symptoms.
“This milestone provides further evidence of the safety and effectiveness of Oxiplex in an ever increasing number of patients around the world,” said John Krelle, FzioMed’s President and Chief Executive Officer. “The fact that sales have continued to grow over many years in a real-world setting is a remarkable achievement and provides the impetus for our supportive FDA approved US IDE study. A large number of clinical sites around the country have expressed interest in the study, which will commence enrollment early this year.”
About FzioMed, Inc.
FzioMed, Inc. is a privately held medical device company that develops, manufactures and markets absorbable surgical biomaterials based on its patented scientific technology. For more information, please contact John Krelle at jkrelle@fziomed.com. You can also visit www.fziomed.com or contact investorrelations@fziomed.com.
FzioMed®, Oxiplex®, Oxiplex/SP® and Interpose® are registered trademarks of FzioMed, Inc.
Contacts
FzioMed, Inc.
John Krelle
jkrelle@fziomed.com
